

KERYX BIOPHARMACEUTICALS INC

Form 4

March 21, 2014

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Oliviero James F III

(Last) (First) (Middle)

C/O KERYX
BIOPHARMACEUTICALS,
INC., 750 LEXINGTON AVENUE

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
KERYX
BIOPHARMACEUTICALS INC
[KERX]

3. Date of Earliest Transaction
(Month/Day/Year)
03/19/2014

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
X Officer (give title below) ____ Other (specify below)

Chief Financial Officer

6. Individual or Joint/Group Filing(Check
Applicable Line)

X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock (Exercise of Stock Options)	03/19/2014		M	36,667	A \$ 2.53 529,528 ⁽¹⁾	D	
Common Stock (Exercise of Stock	03/19/2014		M	18,622	A \$ 2.78 548,150 ⁽¹⁾	D	

Options)

Common
Stock
(Exercise
of Stock
Options)

03/19/2014

M

48,750

A

\$ 4.58 596,900 ⁽¹⁾

D

Common
Stock

03/19/2014

S

154,039

D

\$
15.23 442,861 ⁽¹⁾
⁽²⁾

D

Common
Stock

03/20/2014

S

125,000

D

\$
15.04 317,861 ⁽¹⁾
⁽³⁾

D

Common
Stock

03/21/2014

S

13,444

D

\$
15.11 304,417 ⁽¹⁾
⁽⁴⁾ ⁽⁵⁾

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Oliviero James F III
C/O KERYX BIOPHARMACEUTICALS, INC.
750 LEXINGTON AVENUE

Chief Financial Officer

NEW YORK, NY 10022

Signatures

/s/ James F.

Oliviero, III

03/21/2014

__Signature of Reporting
Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares of restricted common stock.
- (2) Reflects the weighted average sale price. The range of prices for such transaction is \$15.14 to \$15.42.
- (3) Reflects the weighted average sale price. The range of prices for such transaction is \$14.96 to \$15.16.
- (4) Reflects the weighted average sale price. The range of prices for such transaction is \$15.10 to \$15.16.
- (5) Following the transactions reported on this Form 4, Mr. Oliviero holds 304,417 shares of Keryx restricted common stock and 276,639 stock options (of which 168,000 are vested and exercisable).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.